Fresenius SE & Co KGaA (FSNUF) Full Year 2024 Earnings Call Highlights: Strong Growth and ...

Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Upgrade Now

GuruFocus News

Thu, Feb 27, 2025, 12:05 AM 4 min read

Organic Revenue Growth: High single-digit growth for 2024.
EBIT Growth: Double-digit growth, faster than revenue growth.
Biopharma Revenue Growth: 76% year-over-year increase.
EPS Growth: 14% increase in 2024, reversing a 13% decline in 2022.
Leverage: Finished 2024 at the lower end of the leverage corridor.
Dividend Proposal: EUR1 per share for 2024.
Group EBIT Margin Improvement: 180 basis points over the past two years.
Free Cash Flow Increase: More than EUR1.5 billion year-over-year.
Net Debt Reduction: Approximately EUR2 billion reduction in 2024.
Structural Cost Savings: EUR474 million achieved in 2024.
2025 Revenue Growth Guidance: 4% to 6% expected.
2025 EBIT Growth Guidance: 3% to 7% expected.
2025 CapEx Guidance: Around 5% of revenue.

Warning! GuruFocus has detected 7 Warning Signs with FSNUF.

Release Date: February 26, 2025

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Positive Points

Fresenius SE & Co KGaA (FSNUF) achieved high single-digit organic revenue growth and double-digit EBIT growth in 2024.
The company successfully executed strategic portfolio measures, including divesting non-core assets and deconsolidating Fresenius Medical Care.
Fresenius SE & Co KGaA (FSNUF) reported a significant improvement in EPS, with a 14% growth in 2024 compared to a 13% decline in 2022.
The biopharma segment showed impressive growth, with a 76% year-over-year revenue increase, contributing significantly to the company's overall performance.
The company resumed its dividend payments, proposing EUR1 per share for 2024, reflecting its improved financial strength and commitment to shareholder value.

Negative Points

The macroeconomic environment remains volatile, with global markets experiencing rapid changes and shifting trade dynamics.
Fresenius SE & Co KGaA (FSNUF) faces challenges in China due to a slower economic situation and the impact of national volume-based procurement policies.
The company anticipates a negative impact on performance in Q2 2025 due to the inclusion of keto in China's national volume-based procurement process.
Helios Germany faces headwinds from the ending of energy relief payments, which will impact year-over-year comparisons.
The company acknowledges that achieving its ambitious targets will require overcoming significant operational challenges and uncertainties.

Q & A Highlights

Q: Can you provide more details on the visibility of Tyenne volumes and the impact of patient switching based on contracts won? A: Michael Sen, Chairman of the Management Board, explained that they have strong visibility on Tyenne, with over 90% of plans contracted across various channels. The focus is now on execution, including production and shipping, which will ramp up throughout the year, particularly in the second half.

Q: What are the headwinds that could lead to the lower end of the 2025 guidance? A: Michael Sen highlighted several factors, including the loss of Keto volume in China due to the national volume-based procurement program and the absence of energy relief payments for Helios. These factors require the company to work against them to achieve the guidance.

Q: Could you elaborate on the EUR100 million cost savings at Helios and their sustainability? A: Sara Hennicken, CFO, detailed that the savings fall into three categories: clinical process optimization, non-patient-facing areas, and procurement. The procurement savings are expected to materialize quickly, while clinical process optimizations will take longer but are expected to enhance both patient satisfaction and operational efficiency.

Q: How is the biopharma vertical integration progressing, and what is the timeline for in-sourcing the remaining Kabi pipeline? A: Michael Sen stated that vertical integration is a competitive advantage, and they are working on tech transfers to Map science and other facilities. This process is resource-intensive and requires regulatory approval, with significant progress expected by 2026.

Q: What are the drivers behind the strong performance in Clinical Nutrition, and how do you see growth evolving given the tough comps? A: Sara Hennicken noted that Argentina provided a mid-single-digit tailwind, and strong growth was also seen in the US and China. Despite tough comps, Nutrition is expected to remain a strong business, with investments in clinical data to support future growth.

Q: What needs to happen for Kabi to achieve a 20% margin structurally? A: Michael Sen explained that achieving a 20% margin would require continued growth and margin expansion across all segments, including Nutrition, generics, and biopharma. The evolving biosimilar market and competitive dynamics will also play a role.

Q: Can you provide more context on the Ivenix pump rollout and the challenges faced? A: Michael Sen acknowledged the challenges, including FDA recalls, but emphasized that corrective actions are in place. The rollout is progressing, with plans to significantly increase the installed base in 2025.

Q: Are there any further asset disposals planned to improve return on capital employed? A: Michael Sen confirmed that the focus is now on operational improvements and organic growth, with no major asset disposals planned following last year's portfolio restructuring.

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

This article first appeared on GuruFocus.

Terms and Privacy Policy

Your Privacy Choices

Utah Privacy Notice

More Info